SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Hot Topics > Lifecycle management

Lifecycle management

Lifecycle management

As R&D productivity declines and the age of blockbuster medicines reaches an end, the pharmaceutical industry is looking at ways to extend the profitable life of its products up to and beyond patent expiry.

Avon gains on US OK for Ranbaxy’s valacyclovir

02-Dec-2009 - Indian API maker Avon Organics’ share price rocketed 10 per cent on the Bombay exchange yesterday after the US launch of a generic herpes treatment by Ranbaxy Laboratories.

Generics hot up: Cipla in talks with Big Pharma; Takeda mulls M&As

01-Dec-2009 - India’s Cipla is in talks with a number of global pharma players, including Pfizer, about potential generics supply deals.

News in brief

Pharma faces tax hike, says PwC

01-Dec-2009 - The Pharma sector’s shift away from blockbusters could result in higher taxes according to PricewaterhouseCoopers (PwC).

News in brief

Servier’s Irish R&D and manufacturing plant opens

24-Nov-2009 - French drugmaker Servier has opened a new €47m manufacturing and R&D facility in Ireland.

Pfizer may join Japanese generics market in 2011

23-Nov-2009 - Just weeks after completing its billion dollar Wyeth takeover, US drug giant Pfizer has floated the idea of entering Japan’s $5.8bn (€3.9bn)-a-year generic drugs market in 2011 in a bid...

BASF talks novel excipients

18-Nov-2009 - The FDA encourages innovation in excipients to develop new drugs or improve approved therapeutics and IPEC is helping to drive acceptance of these novel products, according to BASF.

Influenza: statins may help, but did aspirin misuse hinder in 1918?

02-Nov-2009 - Early-stage CDC research suggests that the anti-inflammatory properties of cholesterol-busting statin drugs can help mitigate the impact of flu infection.

News in brief

Pfizer, GSK and Bayer accept Ecuador’s plan to break patents

29-Oct-2009 - Late last week Ecuador’s government announced plans to sidestep patents on more than 2,000 drugs, enabling them to produced local or imported as “generics”

Valois discusses what patients want from a device

20-Oct-2009 - Patients want nasal delivery devices that are portable, hygienic and can be used discretely, according to a director at Valois who delivered a talk on the company’s side-actuated product at...

EC GMP directive “still alive”; Cargill

19-Oct-2009 - The EC’s plan to make excipients comply with GMP is “still alive”, according to Cargill which spoke to in-PharmaTechnologist at CPhI about its Zerose erythritol product that it claims can...

Critical gains funding for hGH nasal delivery

19-Oct-2009 - Critical Pharmaceuticals has received a £1.5m ($2.4m) award to develop its hGH nasal spray, the market for which could be sizeable as company’s attempt to differentiate in response to generic...

ACRO wants trials for most biosimilars

15-Oct-2009 - ACRO says while a 12-year exclusivity period for innovative drugs is important for R&D, US legislation should include rules on trials for biosimilars

Stralfors says pack service plan can help drugmakers hit deadlines

15-Oct-2009 - Packaging group Stralfors says its recent collaboration with Novo Nordisk proves that its service plan is ideal for projects with strict time-to-market requirements.

CPhI 2009 show preview

08-Oct-2009 - We look ahead to CPhI 2009 which takes place in Madrid, Spain next week and will showcase the world’s leading ingredients, contract services, machinery and biotech companies.

Labopharm upbeat about depression drug after FDA OKs API maker

08-Oct-2009 - Canadian drugmaker Labopharm says its Italian API maker Gruppo Angelini has resolved all the US FDA concerns about processes used to make a once-a day version of the depression drug...

Genentech licenses SurModics tech for SR Lucentis

07-Oct-2009 - Its new microparticle technology licensing deal with Genentech could be worth as much as $200m (€136m) says US delivery specialist SurModics.

News in brief

Sanofi, Teva and Ratiopharm raided in EC competition probe

07-Oct-2009 - French drug major Sanofi Aventis, Israel's Teva Pharmaceutical Industries and Germany’s Ratiopharm were raided by European Commission (EC) competition officials yesterday as part of an ongoing investigation.

French govt unlikey to relinquish grip on health spending, says BMI

06-Oct-2009 - Despite the government’s “aggressive” promotion of generic drugs, pharmaceutical spending in France will continue to grow, according to new analysis by Business Monitor International (BMI).

Hospira buys facility & filgrastim rights to boost biogenerics

06-Oct-2009 - Hospira has acquired the worldwide rights to filgrastim and a Croatian biologics plant from Pliva, increasing its presence in the biogenerics field, and told in-PharmaTechnologist that further expansions are possible.

FDA proposes cGMP rule for combination products

29-Sep-2009 - The FDA is to establish current good manufacturing practice (cGMP) requirements for combination products to eliminate inconsistencies that could affect product safety and public health.

Controlled-release can deliver for generics firms, says Espicom

03-Sep-2009 - Wyeth’s battles to protect the controlled-release (CR) version of its anti-depressant Effexor are a sign of things to come according to a new Espicom report identifying 30 CR drugs likely...

Biosimilars market to be worth $19.4bn by 2014

03-Sep-2009 - The biosimilars sector is predicted to be worth $19.4bn (€13.6bn) by 2014, by which time the US will have overtaken Asia as the dominant market, according to a report.

Pfizer inaugurates new $214m Swedish biotech plant

26-Aug-2009 - Pfizer’s new $214.8 million (€150m) biotechnology facility in Strangnas, Sweden was inaugurated yesterday, securing the country’s future in the company’s manufacturing network according to global manufacturing president Natale Ricciardi....

Microneedle patch could boost compliance

24-Aug-2009 - Researchers have presented new microneedle drug delivery patches, which, using technology developed in the electronics sector, could improve compliance and treat ocular diseases.

Eastern Europe drug market worth $41bn by 2014; but rules complex

19-Aug-2009 - Eastern Europe’s pharmaceutical market is growing at an impressive rate, but the complex regulatory rules being introduced may make it a less attractive proposition that it first appears, according to...

Key Industry Events

 

Access all events listing

Our events, Events from partners...